AstraZeneca | Fortune

Skip to Content

SIGN IN

Health
As mutant COVID variants multiply, the hunt is on for a ‘universal’ kill-all vaccine
By
Jeremy Kahn
February 19, 2021
Health
What you need to know about severe reactions to COVID vaccines
By
John Lauerman,
Jason Gale,
and others
February 15, 2021
Health
University of Oxford to begin testing AstraZeneca vaccine on children
By
Suzi Ring
and
Bloomberg
February 15, 2021
Health
J&J’s COVID vaccine could make its global debut as soon as next week
By
David Meyer
February 10, 2021
Health
The AstraZeneca COVID-19 vaccine (and possibly others) are ineffective against the South African variant
By
Jeremy Kahn
February 8, 2021
Health
How to stop vaccine nationalism from prolonging the pandemic
By
David Meyer
February 7, 2021
Health
University of Oxford finds AstraZeneca vaccine effective on British variant
By
Eric Pfanner,
James Paton,
and others
February 5, 2021
Health
The AstraZeneca vaccine cuts COVID transmission—and delaying the second dose is a good idea, study finds
By
Jeremy Kahn
February 3, 2021
Health
Why Europe’s summer COVID vaccination target could still be on track
By
David Meyer
February 1, 2021
Health
With supplies running low, Europe approves AstraZeneca’s COVID-19 vaccine for all adults
By
Jeremy Kahn
and
David Meyer
January 29, 2021
Politics
Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals
By
The Associated Press
January 29, 2021
Health
France’s Valneva starts making COVID-19 vaccine in Scotland, ahead of trial results and approval
By
David Meyer
January 28, 2021
Health
What to know about delaying second COVID vaccine shots as countries grapple with limited supplies
By
John Lauerman,
Jason Gale,
and others
January 26, 2021
Health
Furious at AstraZeneca, the EU plans export controls for COVID vaccines made on its home turf
By
David Meyer
January 26, 2021

1 - 14 of 97 results

1 - 14 of 97 results

© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell My Personal Information | Ad Choices
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.